Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Together, Do Markel Corporation (MKL) and Alterra Look Cheap?

Last December, Markel Corporation (NYSE:MKL) shocked the market by announcing a $3.1 billion deal to acquire fellow insurer Alterra Capital.

The deal not only unsettled investors by employing a combination of cash and stock, but it was also significantly larger than the typically small acquisitions that President and CIO Tom Gayner pursues through his Markel Corporation (NYSE:MKL) Ventures subsidiary. The market immediately punished shares of Markel by driving them down as much as 10% that day.

Even so, I remained optimistic in spite of the drop after speculating that the deal might also benefit Markel Corporation (NYSE:MKL) by giving Gayner more flexibility in the ways he invests both the company’s insurance float and shareholder equity, which is a similar perk Warren Buffett enjoys as he invests for the much larger Berkshire Hathaway Inc. (NYSE:BRK.B).

But that’s not all …

As fellow Fool Matt Koppenheffer also pointed out at the time (while noting that Markel Corporation (NYSE:MKL) is often called a “baby-Berkshire”), Alterra’s reinsurance operations also diversify Markel’s insurance segment while making it more Berkshire-esque than ever, especially considering Berkshire also operates its own massive General Reinsurance subsidiary.

Then, perhaps predictably, Alterra Shareholders followed up in February by overwhelmingly voting to approve the merger of the two companies, paving the way for them to receive 0.04315 Markel Corporation (NYSE:MKL) shares plus $10 cash for each share of Alterra they owned, as stipulated in the terms of the buy.

Finally, on May 1, Markel announced it had officially completed the acquisition, noting at the time that the combined company could boast around $23 billion in total assets, with around $6 billion in shareholder equity.

Even so, all the synergies and advantages in the world don’t mean much for investors if a stock is overpriced. So how does the new Markel stack up?

Strength in numbers

Thanks to a recent SEC filing from Markel that provides specific details on the pro forma combined statements of Markel and Alterra, investors now have plenty of new information they can use to put a proper value on the company.

So what does the filing reveal?

First, at the end of the most recent quarter, the two companies actually had combined assets of just over $23.5 billion, with shareholder equity (or book value) listed at $6.5 billion.

Next, if you scroll down a few pages, you’ll see the number of diluted “preliminary pro forma adjusted weighted average common shares outstanding” (try to say that 10 times fast) stood at 14,092,000 as of this past March 31.

Multiply that by Tuesday’s closing price of roughly $537 per share, and that gives us a current market capitalization for the combined companies of around $7.57 billion.

Here’s why Markel looks undervalued

With the shareholder equity I mentioned, that means the combined money-making machine that is Markel and Alterra is currently trading at just over 1.16 times book value — not too shabby for a well-respected financial holding company like Markel.

To put that in perspective, remember that Buffett told the world last year he’d be willing to buy back shares of Berkshire Hathaway if the price to book ratio fell below 1.2. As it stands, and even though many investors still consider it cheap at today’s levels, Berkshire Hathaway stock currently trades around 1.46 times book value.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.